Semaglutide

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) analogue engineered with a C18 fatty-diacid chain that enables binding to albumin, extending its plasma half-life to approximately one week. This structural modification has made it a cornerstone compound in metabolic research, where investigators examine its dose-dependent influence on insulin secretion, glucagon suppression, and gastric emptying kinetics.

Preclinical and translational studies have explored semaglutide's central nervous system effects, particularly its action on hypothalamic GLP-1 receptors associated with appetite and energy balance. Researchers have documented its interactions with the incretin axis, pancreatic beta-cell function, and downstream signalling through the cAMP/PKA pathway, generating a robust body of literature on GLP-1 receptor pharmacodynamics.

In research settings, semaglutide serves as a reference compound for comparing next-generation GLP-1 agonists and multi-receptor co-agonists. Its well-characterised pharmacokinetic profile and receptor selectivity make it an essential tool for understanding metabolic peptide biology.

For research purposes only. Not for human consumption.